Targeting miR-30d reverses pathological cardiac hypertrophy

Targeting miR-30d reverses pathological cardiac hypertrophy

Background: Pathological cardiac hypertrophy occurs in response to numerous stimuli and precedes heart failure (HF). Therapies that ameliorate pathological cardiac hypertrophy are highly needed. Methods: The expression level of miR-30d was analyzed in hypertrophy models and serum of patients with ch...

Full description

Bibliographic Details
Main Authors: Chen, R. (Author), Das, S. (Author), Jin, B. (Author), Li, G. (Author), Li, J. (Author), Sha, Z. (Author), Wang, S. (Author), Wang, Z. (Author), Xiao, J. (Author), Xu, J. (Author), Xu, W. (Author), Yan, Y. (Author), Yang, L. (Author), Yang, T. (Author), Yao, J. (Author), Yuan, W. (Author), Zhu, X. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
miR-30d
Pathological cardiac hypertrophy
Translational research
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items